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Chronic spontaneous urticaria (CSU) is a devastating disease and is associated 
with many co-morbidities and long-lasting suffering. Therefore, patients always 
look for a most efficient therapeutic approach to achieve a full remission. In many 
patients, CSU remain refractory to off-label doses of antihistamines and short 
courses of steroids, and therefore are treated with omalizumab. However, 15–20% 
of severe CSU patients will stay unresponsive to omalizumab and are defined as 
being of un-met needs. In this review we will shed light on the many new drugs 
which are assessed in ongoing clinical trials.
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1. Introduction
Chronic spontaneous urticarial (CSU) with or without angioedema, is a 
condition which lasts more than 6 weeks, without an apparent trigger. It results 
from a pathogenic over-activation of dermal mast cells and basophils, followed 
by their degranulation and the release of pro-inflammatory mediators (mainly 
histamine) inducing the appearance of transient itchy wheals, and occasionally 
episodes of angioedema. The prevalence of CSU is estimated to be between 
0.5-1percent in the general population, with an incidence of 0.10 to 1.50 per 1000 
person-years. It predominantly affects female, with symptom onset occurring 
mainly between 20 and 40 years [1]. Earlier studies reported on CSU lasting over 
one year in more than 70% of cases and continuing to exist in 14% of them after five 
years. CSU duration was associated with the presence of angioedema and disease 
severity. In a recent study, younger CSU patients (22 ± 16 years) tended to have a 
significantly longer course, were in 16% of patients, CSU symptoms lasted over ten 
years [2, 3]. In addition to its prolonged duration, CSU severely affects quality of 
life and is associated with comorbidities such as lack of sleep, impairments in work 
productivity, and depression/anxiety. In one study about 50% of patients with CSU 
were diagnosed with one or more psychosomatic disorders, the most frequent of 
which was anxiety, followed by depressive and somatoform disorders [4, 5]. The 
prevalence of rheumatoid arthritis, systemic lupus erythematosus, thyroiditis 
and vitiligo were found to be significantly increased in CSU patients [6]. Patients 
without any evidence of comorbidities at the time of their CSU diagnosis had an 
increased risk of developing mast cell-mediated diseases including atopic diseases 
[7]. Many studies have focused on the importance of clinical and laboratory 
biomarkers for the assessment of CSU severity and the evaluation of treatment 
efficacy. Clinical manifestations such as asthma and thyroid disease were associated 
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with higher disease severity and duration [8]. Laboratory markers, namely, 
C-reactive protein (CRP), autologous serum skin test (ASST), basophil activation 
test (BAT, D-dimer levels and total serum IgE are all potential blood biomarkers 
that are useful for CSU management [9]. Many CSU patients continue to suffer 
from symptoms of pruritus, urticaria, and angioedema despite the acceptable up 
dosing of second-generation antihistamines (up to fourfold) [10]. Recurrent short 
courses of steroids were also reported to have only a short-term beneficial effect 
in severe CSU patients. Current treatments are considerably effective in achieving 
good response and favorable remission, however, many CSU patients are still 
refractory to these available treatments. This is why, it is extremely important to 
identify and understand underlying disease mechanisms, in order to achieve better 
therapeutic outcomes. In addition to a brief summary covering the pathogenesis 
of CSU, and the currently used therapies, this chapter will focus on emerging new 
therapies, some of which are being studied in on-going clinical trials, and others 
that are being assessed as potential candidates for treatment.
2. Pathophysiology
At the very beginning (four decades ago), CSU was considered to be a T-cell 
mediated disorder, supported by the finding of rich CD4+ T-cell infiltration in 
the skin of CSU patients [11]. The involvement of activated T-cells in peripheral 
blood of CSU patients, namely the increased expression of CD40 ligand on T-cells 
similarly to what we find on activated T-cells from patients suffering from active 
systemic lupus erythematosus and other autoimmune diseases was also reported 
[12]. In concert with this, there are studies showing an increased switch of Th1 
to Th17 in the peripheral blood of CSU patients in correlation with CSU disease 
severity, and IL-17 levels are significantly higher in the autologous serum skin test 
(ASST) positive than ASST negative CSU patients. Plasma levels of interferon-γ 
(IFN-γ), IL-2 and IL-21 were also found to be significantly higher in ASST-positive 
CSU subgroups, known to involve the positive regulation of the Janus-kinase-signal 
transducer and activator of transcription (JAK/STAT) signaling pathway [13]. In a 
recent study using Kunming mice (a model of CSU), a longer duration and higher 
intensity of pruritus was demonstrated to be in association with enhanced levels 
of eosinophils, inflammatory cytokine expression and activated the JAK/STAT 
signaling pathway. This was found to be in mice overexpressing IL-9 and IL-10, 
contributing to the development of CSU by signaling the JAK/STAT pathway [14]. 
Commensurate with this, is the later finding of antigen/disease-specific auto-
reactive CD4 + T cells that target FcεRIα in most patients with CSU, with a cytokine 
secretion profile typical of aTh1 immune response. This is compatible with the 
earlier finding of IgG autoantibodies to FcεRIα on dermal mast cells and basophils, 
supporting the concept that CSU is an autoimmune disorder probably mediated by 
auto-reactive T cells. IFN-γ and autoantibody responses to FcεRIα were found to be 
inversely related, with IFN-γ responses being detected earlier than autoantibodies 
in the course of CSU. This finding of inverse relationship between auto-reactive 
T-cell responses and autoimmunity suggests these responses to be different stages 
in the pathogenesis of CSU [15]. In a very recent study we found that increased 
numbers of CD4 + T cells and mast cells were present in both lesional and non-
lesional skin of CSU patients when compared with the healthy controls. Both types 
of cells were strongly positive for IL-17A and found to be in close proximity to each 
other [16]. With respect to the aforementioned, autoimmunity in CSU patients is 
reported to be found in at least 50% of cases. Two types of autoimmunity have been 
documented and supported by numerous reports. The first (type I) is driven by 
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IgE auto-antibodies against thyroid antigens and/or auto-allergens, defined by the 
presence of anti-TPO antibodies. In parallel to this, is the finding of type IIb auto-
immunity characterized by the binding of IgG auto-antibodies (recently also IgA 
and Ig M) to IgE and/or FcɛRIα on mast cells [17–19]. Both types are followed by the 
intense activation and degranulation of mast cells and the release of inflammatory 
mediators in the skin that are able to induce itchy wheals and angioedema. Among 
the many mediated agents, histamine, pro-inflammatory cytokines and chemokines 
are the most frequent [20]. Basophils and Eosinophils have recently been included 
among other cells actively involved in the pathogenesis of CSU. In this respect, 
peripheral blood basopenia is frequently reported in association with CSU disease 
severity. It has been postulated that this is a result of the migration of basophils 
from blood to the skin of active CSU patients. Basopenia resolves in parallel with 
CSU remission and therefore may become a suitable marker for follow-up [21]. 
Recent evidence suggests that eosinophils may also play role in the pathogenesis of 
CSU. Both eosinophils and eosinophil granules were displayed in lesional skin of 
CSU patients. This is in contrast to allergic rhinitis and asthma where peripheral 
blood eosinophilia is a characteristic finding, while in CSU, peripheral blood eosin-
openia is observed in association with disease severity. As in the case of basopenia, 
depletion of active eosinophils and their shift to the skin of CSU patients is the most 
accepted mechanism of this phenomenon [22]. The issue of how all these cells, and 
mechanisms, are linked, and how they act at onset or during the persistence of CSU 
is extremely complex. However, current therapies, targeting free IgE, mast cells and 
T cells are reported to be tremendously efficient in inducing CSU remission.
3. Current therapies for CSU
The introduction of the non-sedative anti-histamines replacing the first genera-
tion (sedative) one was a giant step forward in the treatment of CSU. At a later 
date, H1-antihistamine up-dosing was established and shown to be safe and of 
better efficacy. However, even when up-dosing was increased fourfold, the rate 
of non-responders remained high, thereby suggesting that additional treatments 
were needed [23]. As early as 1991, targeting T-cells by cyclosporine A (CsA) was 
shown to be highly effective in severe cases of CSU [24]. Later on, we demonstrated 
that low doses of CsA (2–3 mg/ml) given for three months were both extremely 
beneficial and had a low prevalence of side-effects. In some patients, we could 
demonstrate a long-lasting full remission, while in others it was even curative [25]. 
The efficacy of CsA was established by many double-blind, randomized studies. 
Symptom scores significantly improved in the CsA group over with placebo. CsA 
was well tolerated at daily doses of 3 mg/kg. Side effects such as hypertension and 
increased serum creatinine were rare [26]. In addition, the efficacy and safety 
of CsA in CSU was evaluated by a meta-analysis of eighteen studies. A low-dose 
(2–3 mg/kg/d) was considered to be both beneficial and safe, and adverse events 
appear to be dose dependent and occur more frequently in patients that have been 
treated with moderate doses (4–5 mg/kg/d) [27]. In a recent study, the prediction 
of beneficial response to CsA treatment, was assessed using, positive ASST, plasma 
D-dimer levels, IL-2, IL-5 levels and total IgE level. Decreased plasma D-dimer 
levels, and decreased serum IL-2 and IL-5were reported to be correlated with 
clinical improvement after CsA treatment [28]. While cyclosporine A is still used 
in cases with severe CSU, the fear of side effects, mainly in those with mild hyper-
tension or diabetes, has limited its usage, allowing omalizumab (an IgG-anti-IgE 
monoclonal antibody), approved for the treatment of anti-histamine-refractory 
CSU in 2014 to become the preferable option in treating CSU. In the European 
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Academy of Allergology and Clinical Immunology, Global Allergy and Asthma 
European Network, European Dermatology Forum, and World Allergy (EAACI/
GA2LEN/EDF/WAO) guidelines for the treatment of CSU, it is recommended 
that omalizumab should be added to off-label doses of anti-histamines when CSU 
is inadequately controlled [29, 30]. Cyclosporine A remains the final option for 
those considered to be omalizumab failures. The main mechanism through which 
omalizumab acts, is its ability to bind soluble IgE and the down regulation of FcεRI 
expression on skin mast cells. This is followed by decreased mast cell activation and 
degranulation. In this respect, higher levels of FcεRI expression, predict a faster 
response to omalizumab. In addition higher levels of total serum IgE were shown 
to be associated with a greater responsiveness to omalizumab [31]. While it is well 
accepted that a complete response to the standard dose of omalizumab (300 mg/
month) is observed in about 59% of patients, 15% of treated patients still remain 
resistant to this dose of omalizumab [32]. In many studies, up dosing of omali-
zumab to 450 mg/month was shown to achieve better clinical respnses with a good 
safety profile [33]. Options of higher doses of cyclosporine A or the combination of 
omalizumab and cyclosporine A were also reported in few case reports in severe and 
refractory to all of the above mentioned approaches. Un-met needs and the require-
ment for new treatments in still refractory CSU are the subject of many on-going 
clinical trials in which targeting new relevant pathways is assessed.
4. New drugs in ongoing clinical trials
4.1 Anti IgE
4.1.1 Ligelizumab
Ligelizumab (QGE031) is a new monoclonal antibody directed against the Cε3 
domain of IgE, which in preclinical and in phase I clinical studies demonstrated 
its 50-fold greater affinity to IgE in vitro and six- to nine-fold greater potency in 
vivo compared to omalizumab. This affinity difference is caused due to epitope 
differences between ligelizumab and omalizumab that contribute to their distinct 
qualitative IgE-receptor profiles. Ligelizumab was superior in its ability to suppress 
IgE binding to FcεRI, basophil activation, and IgE secretion by B cells [34]. It was 
also shown that Ligelizumab provided a longer suppression of free and cell-bound 
IgE [35]. Omalizumab was shown to inhibit the interaction of IgE-FcεRII (CD23) 
more efficiently than Omalizumb, and this finding might explain the superior 
anti-asthmatic effect of omalizumb, considering the role of CD23 in lung inflam-
mation [34]. In order to further assess its efficacy in CSU, a phase IIb dose-finding 
trial was designed for the efficacy and safety of ligelizumab. Doses of 24 mg, 72 mg, 
and 240 mg every four weeks were compared to the omalizumab standard dose of 
300 mg every four weeks and to placebo in 382 adult patients with CSU. Clinical 
beneficial effects were evaluated by using - UAS7 (Urticaria Activity Score) and 
HSS7 (Hives Severity Score). The percentage of patients with a complete control of 
their hives (HSS7:0) and a complete control of their symptoms (UAS7:0) at week 
12 was significantly higher in all ligelizumab arms (24 mg, 72 mg, 240 mg) com-
pared with omalizumab (300 mg) and the placebo. The question regarding the low 
complete response rates with omalizumab was attributed to the high percentage of 
patients with an autoimmune pattern and angioedema. Adverse events rates were 
similar in all groups, except for a slightly higher incidence of local reaction at the 
injection site of ligelizumab 240 mg compared to omalizumab [36]. Patient’s follow 
up in this clinical study revealed that among patients who achieved an UAS7 ≤ 6 at 
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week 20, the beneficial therapeutic response was maintained for a median of 16, 
8 and 8 weeks with ligelizumab 240 mg, 72 mg, and omalizumab, respectively. In 
addition, a 1-year extension phase of the above clinical study showed that in patients 
with UAS7 ≥ 12 who received ligelizumab 240 mg every 4 weeks (NCT02649218), 
the UAS7 ≤ 6 score response was maintained for a median period of 28 weeks [37]. 
Moreover, the treatment with ligelizumab was superior in other clinical measures 
when compared with omalizumab, namely, a decrease in the use of rescue medica-
tion [38] a greater and sustained efficacy in reducing angioedema at week 12 (the 
percentage of angioedema-free patients with ligelizumab 72 mg, 240 mg, omali-
zumab 300 mg, and placebo, was 87.5%, 94.9%, 76.3%, and 68.3%, respectively 
[39]. Several Phase III clinical trials (NCT03580356, NCT03580369, NCT03437278, 
NCT04210843) are currently in progress in order to further investigate the efficacy 
and safety of ligelizumab 72 mg and 120 mg when compared with omalizumab 
300 mg and a placebo in CSU adolescent and adult patients up to 52 weeks. In Japan, 
in adult CSU patients who failed to response to H1-anti-histamines, are part of 
another phase III, open-label, and single-arm study of ligelizumab that is currently 
in progress (NCT03907878). It is hopeful that these studies and the extension phase 
study with ligelizumab will better characterize its usage in re-treatment, and self-
administration, as well as its its benefit as a monotherapy.
4.1.2 UB-221
Another new monoclonal antibody against IgE, UB-221, has up to eightfold 
greater affinity for free IgE in comparison with omalizumab. This new compound 
is currently being investigated for safety, tolerability, pharmacodynamics and 
pharmacokinetics in an ongoing phase I clinical trial in adult patients with CSU. 
The study is composed of single doses [0.2, 0.6, 2, 6, 10 mg/kg UB-221] given 
intravenously (IV) vs. a placebo (NCT03632291, NCT04175704) [40].
4.2 B cells
4.2.1 Bruton’s tyrosine kinase (BTK) inhibitors
Bruton tyrosine kinase (BTK) is a tyrosine kinase which was found to play a 
major role in B cell development. At a later date, it was found to be expressed in 
various hematopoietic cells including macrophages, mast cells, and basophils.  
In the context of CSU pathogenesis, BTK was also found to play a major role in the 
FcεR activation and signaling in mast cells [41, 42]. BTK inhibitors are widely used 
today to treat several B cell malignancies and auto immune disorders [43]. Out of 
the many known BTK inhibitors, four (ibrutinib, dasatinib, AVL-292, CNX-774) 
are recognized to be effective suppressors of IgE-induced activation and histamine 
release from basophils and mast cells [44]. Ibrutinib (420 mg/day), was assessed in 
patients suffering from peanut/tree nut allergy and reported to suppress skin test 
responses to these food allergens within seven days, and without any discernable 
adverse events. No serious adverse events 100. Upon considering of the pivotal role 
of FcεRI signaling in CSU, it seems that the use of BTK inhibitors for CSU could be 
a potential new treatment option. LOU064 (remibrutinib), a more selective BTK 
inhibitor is being investigated in ongoing phase II clinical trials (NCT03926611, 
NCT04109313) for its efficacy and safety in adult patients with CSU. In an in-vitro 
study, the binding of BTK by remibrunitib was more efficient than fenebrutinib, 
thus it has a faster onset of action and its effects are maintained longer [45]. 
Another phase II study, investigating a new BTK inhibitor (fenebrutinib 200 mg 
orally twice a day), in adult patients suffering from CSU, has recently been 
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completed. The results of this study indicated that at week 8, a marked improve-
ment of the UAS7 was achieved at 200 mg twice a day compared with the placebo 
group [33].
4.2.2 Anti-CD20
Rituximab (RTX) is a well-known monoclonal antibody directed against CD20. 
It causes the depletion of mature and memory B cells through several mechanisms 
such as CDC and ADCC. For many years, it has been used to treat B cell hematologi-
cal malignancies and autoimmune diseases such as- rheumatoid arthritis (RA), 
and pemphigus vulgaris [46]. Due to the autoimmune nature of CSU, it seems 
reasonable that the reduction of memory B cells and a subsequent decrease of the 
autoantibodies due to Rituximab, could well become a beneficial treatment option, 
particularly in autoimmune CSU. So far, only five patients in whom severe CSU 
refractory to immunosuppressive treatments, have been treated with rituximab 
[47–51]. The treatment regimen in these patients was either as used in lymphoma 
(375 mg/m2 weekly for 4 weeks) or as used in the RA protocol (two doses of 
1000 mg with a 2-week interval). Four patients responded well to this treatment, 
and only one failed. However, a phase I/II open-label trial (NCT00216762) was 
terminated due to safety concerns. To date, there are no ongoing clinical trials on 
Rituximab in CSU patients. It appears that Rituximab could be reserved for future 
use as an alternative treatment option in patients with very severe, and treatment-
resistant CSU.
4.3 Basophils, eosinophils and Th2 cells
4.3.1  Chemo attractant receptor-homologous molecule expressed on Th2 (CRTH2) 
inhibitors
CRTH2 is the prostaglandin D2 (PGD2) receptor that is secreted from mast cells 
upon activation and degranulation. CRTH2 is normally expressed on eosinophils, 
basophils, and Th2 cells. The signaling pathways following PGD2-interaction\liga-
tion to CRTH2 results in the stimulation and chemotaxis of basophils and eosino-
phils, Th2 response, and the increase in the amount of histamine released from 
basophils [52, 53]. In patients suffering from CSU, membrane CRTH2 expression 
on basophils and eosinophils, was found to be extremely low, which was presum-
ably attributed to the internalization of CRTH2 upon PGD2 binding. These results 
suggested a role for PGD2 via CRTH2 ligation in CSU [54]. A particular CRTH2 
gene polymorphism was demonstrated in several patients suffering from CSU, and 
these specific patients needed high doses of anti-histamines in order to control 
CSU [53]. These findings further establish a role for CRTH2 in CSU pathogenesis, 
suggesting the relevance of its targeting. Based on these considerations, a new oral 
CRTH2 antagonist, AZD1981, was generated and used for the treatment of CSU 
in a clinical trial. In a phase II, double-blind, placebo-controlled trial, twenty-six 
CSU patients were enrolled and completed the 4-week treatment period with either 
AZD1981 (40 mg three times daily) or a placebo. A clinical assessment of UAS7 and 
ISS7 scores revealed a significant reduction in these scores when compared with 
the baseline scores before treatment. However, the primary endpoint (a reduction 
in UAS7 ≥ 9.5 points when compared with the baseline) was not achieved in this 
study. No significant differences were observed in terms of anti-histamines use or 
the frequency of angioedema-attacks between the treatment and control groups. 
No serious adverse events were observed and the overall treatment was well toler-
ated [52], Regarding biological effects, the treatment with AZD1981 significantly 
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inhibited PGD2-mediated eosinophil migration to the skin. Despite failing to meet 
the primary endpoint, future studies evaluating the efficacy of AZD1981 with 
longer treatment duration and higher doses are needed.
4.3.2 Spleen tyrosine kinase (SYK) inhibitors
Spleen tyrosine kinase (SYK) is a pivotal player that regulates histamine 
release and the synthesis of immune mediators (e.g. leukotriene, prostaglandin) 
upon FcεRI activation in mast cells [55]. Nowadays, oral SYK inhibitors such as 
fostamatinib are used extensively in the treatment for autoimmune diseases such 
as immune thrombocytopenic purpura, chronic graft-versus-host disease and 
Rheumatoid Arthritis. A new intranasal SYK inhibitor, R112, was also proven 
to suppress FcεRI-related mediator release following mast cell degranulation, 
thereby suggesting that SYK inhibitors are extremely efficient in suppressing 
mast cell degranulation [56]. Based on the above data the use of SYK inhibitors 
to successfully treat CSU patients was not surprising. The first study to use SYK 
inhibitors was an in vitro study where a topical SYK inhibitor, was used in an ex 
vivo human skin model, GSK2646264. In this study it was shown that this inhibitor 
blocked the histamine release from mast cells through IgE signaling [57]. Following 
this study, a randomized, placebo-controlled phase I trial (NCT02424799) was 
conducted in order to evaluate the efficacy and safety of GSK2646264 0.5% and 
1% topical cream in patients with CSU and cold urticarial. The results of this 
study are not available yet. In another in vitro study, the expression level of SYK 
was evaluated in mast cells from CSU patients. These patients were categorized 
according to the clinical out- come as responders and non-responders; the degree 
of basophil’s histamine release and the expression of SYK protein in mast cells. This 
study found that the SYK protein was expressed significantly higher in responders 
when compared with non-responders and healthy controls. It also revealed that the 
increased expression of SYK was correlated with the spontaneous histamine release 
from mast cells in these patients [58].
4.4 Cytokine inhibitors
4.4.1 Anti IL-1
The IL-1 cytokine family in general and IL-1α and IL-1β, specifically have 
pro-inflammatory effects, which are neutralized by using the IL-1R antagonist. 
[59]. Several IL-1 mutations (NLRP3 genes) are collectively defined as auto-inflam-
matory syndromes, which cause the increased secretion of IL-1β. This is associated 
with a heterogeneous syndrome (NLRP3-AID (consisting of familial cold autoin-
flammatory syndrome, Muckle–Wells syndrome, and chronic infantile neurological, 
cutaneous and articular syndrome. The urticarial-like rash is one of most common 
hallmarks of these syndromes [60, 61]. IL-1 inhibitors, such as canakinumab 
(monoclonal antibody against of IL-1β), anakinra (recombinant IL-1R antagonist), 
and rilonacept (IL-1α/β blocker) are very effective in reducing inflammation and 
the clinical spectrum of these syndromes [62]. It is worth mentioning, that the 
emerging knowledge regarding the use of IL-1-blocking agents in the treatment 
of Schnitzler’s syndrome, is characterized by the presence of urticarial rash and 
systemic inflammation [63, 64]. In on-going clinical trials, the effectiveness and 
safety of RPH-104 (a novel molecule against IL-1β), rilonacept, and canakinumab 
has been confirmed in Schnitzler syndrome (NCT04213274), acquired cold-contact 
urticaria (NCT02171416), and CSU (NCT01635127). The results of these trials 
have not yet been published. In few sporadic reports, anti-IL-1drugs were shown to 
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be beneficial in CSU patients, who remained resistant to all classical therapies for 
CSU [65]. A new somatic mutation in NLRP3 was recently reported in two elderly 
patients with long-standing, refractory CSU associated with fever and increased 
CRP. Both of these patients improved dramatically following the usage of anakinra. 
As a result, it is assumed assumed that in patients with refractory urticaria and 
markers of systemic inflammation (a possible underlying NLRP3-related disorder), 
anti-IL-1 treatment requires further evaluation [66].
4.4.2 Anti-IL-4/13
In the process of Th2 differentiation several cytokines are produced. The most 
important cytokines in this process are interleukin-4 and IL-13 [59]. Dupilumab, 
a new monoclonal antibody directed against the alpha subunit of IL-4 and IL-13 
receptors, was recently approved for the treatment of asthma, nasal polyposis, 
and atopic dermatitis [67]. Increased levels of IL-4 were recently demonstrated 
in patients with CSU, thereby suggesting a pathogenic role of both Th1/Th2 
responses and raising the option of treating CSU with Dupilumab [68]. A recent 
case report involving six patients with concomitant atopic dermatitis and CSU 
who were refractory to high dose of omalizumab (600 mg\4 weeks) documented 
their successful treated with Dupilumab. In this report, it was postulated that the 
beneficial therapeutic effect of Dupilumab could be the result of its blocking Th2 
inflammatory pathways by inhibiting IL-4 and IL-13, respective [69]. Currently, 
there are three ongoing, phase II/III clinical studies investigating the efficacy and 
safety of Dupilumab in CSU (NCT03749135, NCT04180488 (EFC16461-CUPID)) 
and cholinergic urticaria (NCT03749148) unresponsive to a high dosage of antihis-
tamines and omalizumab.
4.4.3 Anti IL-5
Eosinophils, are considered to have a pivotal role in the pathogenesis of CSU. 
Many reports have demonstrated elevated numbers of eosinophils in urticarial 
lesions when compared with normal skin. Their contribution to CSU pathogenesis 
is probably achieved through interactions with mast cells, the secretion of histamine 
and other inflammatory mediators and the activation of the coagulation cascade 
[70]. The important role of interleukin-5 (IL-5) in eosinophil development and 
maturation, as well as in increased chemotaxis towards skin urticarial lesions has 
been well documented [59]. Several monoclonal antibodies were recently approved 
for the treatment of eosinophil related airway diseases (e.g. asthma, Churg-Strauss 
syndrome, nasal polyposis etc.) by targeting IL-5 (reslizumab, mepolizumab) or 
its receptor, IL-5R (benralizumab). These drugs were recently used in three CSU 
patients who were refractory to classical therapies; two patients responded well 
and showed a significant improvement with Reslizumab and mepolizumab [71, 
72], while the other patient who suffered from symptomatic dermographism (SD) 
benefited from their treatment with benralizumab [73]. In a recent single-blind, 
repeated measures study, 12 CSU patients were treated with benralizumab (30 mg 
subcutaneously) every 4 weeks for 12 weeks following a single dose of a placebo. 
Among the nine patients who completed the study, five had complete response. 
Their UAS7 and CU-Q2oL scores improved significantly with benralizumab when 
compared with the placebo [74]. Gene-expression analysis in patients with CSU 
following benralizumab treatment demonstrated the normalization of SIGLEC-8 
expression and IL-4/5 induced inflammation [75]. Although the results imply 
that eosinophils play a role in CSU, the exact mechanism of action has not yet 
been understood. Two clinical trials investigating the efficacy of benralizumab 
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(NCT03183024) and mepolizumab (NCT03494881) in CSU are still in progress, 
and their results are not yet available. Regarding benralizumab, a phase IIb study 
(ARROYO Trial- D3259C00001) is set to start soon.
5. Potential therapeutic approaches
5.1 Eosinophils, mast cells, basophils
5.1.1 Siglec-8
The Siglecs are a family of sialic-acid-binding immunoglobulin-like lectins, 
which are thought to promote cell–cell interactions and regulate the functions of 
cells in the innate and adaptive immune systems through glycan recognition. These 
proteins have regulatory effects on intercellular and intracellular signaling such as 
the inhibition of cellular proliferation/activation and the induction of apoptosis 
[76, 77]. Siglec-8 is highly and selectively expressed by eosinophils, but it became 
clear that it is also expressed by human mast cells and weakly, but consistently, by 
human basophils. Studies showed that the activation of Siglec-8 induces eosinophil 
apoptosis (in a caspase-, mitochondrial-, and reactive oxygen species–dependent 
way). It was also shown that activated eosinophils are especially sensitive to Siglec-
8-induced death [78]. It also inhibits the release of FcεRI-mediated histamine and 
PGD2 from mast cells [79, 80]. In a recent phase I, randomized, placebo-controlled 
study conducted with more than 50 healthy volunteers, a single dose of a monoclonal 
anti-Siglec-8 antibody, namely- AK002 (autolimab) (0.001, 0.003, 0.01, 0.03, 0.1, 
0.3, and 1 mg/kg IV), resulted in the complete depletion of circulating eosinophils 
within one hour from the infusion. This effect was maintained for up to 84 days only 
in the group who received 1 mg/kg. This result pointed to a possible administration 
schedule of AK002 at monthly or quarterly intervals [81]. Additionally, in another 
additional study it was also demonstrated that treatment with AK002 provided 
symptomatic and histologic improvement in patients with eosinophilic esophagitis 
[82]. Taking this into consideration, a phase IIa study in CSU and CIndU (cholinergic 
urticaria and symptomatic dermographism) patients was conducted. These patients 
received six doses of AK002. At week 22, following treatment, based on changes in 
UCT score - the response rates in CSU patients were the following, complete + partial 
response in 92% and 86% in omalizumab-naive (n = 14) and omalizumab refrac-
tory (n = 12) patients, respectively. In the 12-month open-label extension phase, 
the response was sustained. No adverse events were observed, with only mild-to-
moderate infusion-related reactions recorded [83, 84]. These results suggest that in 
the future, anti-Siglec-8 antibodies might be a treatment option for CSU patients, 
who are either omalizumab naïve or refractory to omalizumab.
5.1.2 Other molecules (SHIP-1, PI3K, CD200)
Many new regulatory molecules are recently evaluated for their potential 
inhibitory effect on mast cell degranulation. Some of them are under development 
and are to be included in the pipe-line of clinical trials for the treatment of CSU. 
Among these molecules are SHIP and CD200R, which deserve our attention. It has 
been shown that SHIP-negative mast cells are more likely to degranulate following 
IgE binding [85]. The inhibitory effects of SHIP-1 occur through the hydrolysis of 
phosphatidylinositol 3, 4, 5-trisphosphate by limiting the entry of extracellular 
calcium, thereby decreasing phosphoinositide 3-kinase (PI3K)-mediated mast 
cell activation [86–88]. CD200R is a member of the Ig supergene family that is 
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primarily expressed on myeloid cells. In vivo studies demonstrated that CD200R 
is an inhibitory receptor that is capable of regulating the activation threshold of 
inflammatory immune responses. Furthermore, CD200R was also shown to be 
expressed on mouse and human mast cells and that engagement of CD200R by 
agonist Abs or ligand results in a potent inhibition of mast cell degranulation and 
cytokine secretion responses. The proposed mechanism for that effect was possibly 
due to the inhibition of FcεRI activation that was observed both in vitro and in vivo. 
[88] Considering their regulatory functions on mast cells, the use of SHIP, CD200R 
antibodies, or PI3K inhibitors for the treatment of CSU is of great interest.
5.1.3 Anti-histamine H4 receptor
The emerging field of histamine H4 receptors in allergy and clinical 
immunology is continuously growing. H4 histamine receptor, is a member of the G 
protein-coupled receptor superfamily that is largely expressed in haematopoietic 
cells and plays an increasing role in the regulation of immune responses. H4 
receptors modulate eosinophil migration and selective recruitment of mast cells 
that leads to an increased histamine-release and chronic inflammation. It is also 
involved in T cell differentiation thereby is involved in many immunomodulatory 
pathways. The observation that H4 is a histamine receptor on many immune cells 
shed light on the potential of their targeting in inflammatory disorders, such as 
allergy, chronic pruritus and autoimmune diseases e.g. CSU [89]. Several ongoing 
clinical studies currently taking place are aimed at evaluating the beneficial effect 
of targeting H4 receptors in patients suffering from atopic dermatitis and pruritus 
(JNJ-7777120, ZPL-3893787). Preliminary results have indicated a significant 
reduction in histamine-mediated scratch and Th2-induced inflammation in atopic 
dermatitis [90, 91]. These results are encouraging and indicate the need to further 
evaluate any potential benefits of these drugs in the treatment of CSU.
5.1.4 Mas-related gene X2
MrgX2 is a member of Mas-related genes that is primarily expressed in human 
dorsal root ganglia and mast cells and is activated by basic peptides. MrgX2 is a 
multi-ligand receptor responding to various exogenous and endogenous stimuli. As 
they are highly expressed on skin mast cells, MRGPRX2 triggers their degranulation 
and release of pro inflammatory mediators, thus promoting multicellular signaling 
cascades, such as itch induction and transmission in sensory neurons. The expres-
sion of MRGPRX2 by skin mast cells and the levels of the MRGPRX2 agonists (eg, 
substance P, major basic protein, eosinophil peroxidase) are up-regulated in the 
serum and skin of patients with inflammatory and pruritic skin diseases, such as 
CSU and atopic dermatitis. Thus, MRGPRX2 and its agonists might possibly be 
potential biomarkers for the progression of cutaneous inflammatory diseases and 
the response to treatment in the future. In addition, they may well represent prom-
ising targets for the prevention and treatment of signs and symptoms in patients 
with skin diseases or drug reactions [92].
6. Anti-IgE, B cells
6.1 Quilizimab
Quilizumab, is another new humanized monoclonal antibody directed specifi-
cally against membrane-bound IgE. This molecule was also evaluated for its efficacy 
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and safety for the treatment of CSU in a phase II trial. Unfortunately, following a 
20-week treatment with quilizumab 450 mg or a placebo every 4 weeks, no statis-
ticallly significant differences were observed in all clinical scores ISS7, HSS7, and 
UAS7 – between the two groups. Moreover, even in the minimally important differ-
ence (MID) range the quilizumab group also failed to attain significant differences. 
[93]. Thus, further development of quilizumab for CSU was discontinued.
6.2 T cell related therapies
6.2.1 TSLP
The expression of thymic stromal lymphopoietin (TSLP), a promotor of Th2 
response, was proven to be increased in patients with CSU, thus making the anti-TSLP 
monoclonal antibody, tezepelumab, a potential treatment alternative for CSU [94, 95].
6.2.2 Anti-IL-17
The finding of increased blood levels of IL-17 in CSU patients was previously 
reported to be in association with CSU severity. This encouraged us to assess the 
status of IL-17 in the skin of CSU patients, thus, demonstrating increased IL-17 
expression in CD4+ T cells and mast cells of both lesional and non-lesional skin of 
severe CSU patients. With this in mind, eight severe CSU patients (refractory to 
all approved therapies and steroid dependent) were treated with the anti-IL-17A 
antibody, secukinumab, demonstrating a significant improvement in CSU disease 
activity and were able to discontinue steroids. Future studies should be planned in 
order to expand this promising therapeutic approach [16, 96].
7. Summary
The need for new treatments evolve from the fact that 15–20% of severe CSU 
patients will stay unresponsive to Omalizumab and are defined as being of un-met 
needs. Thus, a better understanding of the complexity of CSU pathogenesis led to 
the development of many new treatment options. In this chapter we reviewed the 
known and the ongoing clinical studies of the new treatments for severe CSU. We 
expect that some of these strategies will be efficient and will be added to the market 
of the existing therapies.
Urticaria - Diagnosis and Management
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